ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Topalian on the PD-1 Immunotherapy BMS-936558

Suzanne L. Topalian, MD
Published: Friday, Jun 22, 2012

Suzanne Topalian, MD, Professor of Surgery and Oncology at the Johns Hopkins University School of Medicine, discusses the possible implications of the preliminary data for the investigatory PD-1 targeted immunotherapy BMS-936558, which was presented at the 2012 ASCO Annual Meeting.

Topalian believes that the early-stage results are big news for immune therapy. The trial found that the agent was active in patients with advanced melanoma, renal cell carcinoma, and non-small cell lung cancer. However, the full spectrum of tumors this agent is effective against is not yet fully known and will require further investigation.

Although preliminary, the trial demonstrated the efficacy of inducing tumor regression through the reeducation of the immune system.
 
Suzanne Topalian, MD, Professor of Surgery and Oncology at the Johns Hopkins University School of Medicine, discusses the possible implications of the preliminary data for the investigatory PD-1 targeted immunotherapy BMS-936558, which was presented at the 2012 ASCO Annual Meeting.

Topalian believes that the early-stage results are big news for immune therapy. The trial found that the agent was active in patients with advanced melanoma, renal cell carcinoma, and non-small cell lung cancer. However, the full spectrum of tumors this agent is effective against is not yet fully known and will require further investigation.

Although preliminary, the trial demonstrated the efficacy of inducing tumor regression through the reeducation of the immune system.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x